Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
ACE-031 (Ramatercept)
Overview
ACE-031 is a recombinant fusion protein combining the extracellular domain of the activin receptor type IIB with a human IgG1 Fc domain. This soluble receptor acts as a decoy to bind and neutralize myostatin, activin, and other negative regulators of muscle growth.
Mechanism of Action
By inhibiting these TGF-beta superfamily ligands, ACE-031 was designed to promote muscle hypertrophy in conditions characterized by muscle wasting.
Research Summary & Key Findings
Phase 2 clinical trials in postmenopausal women and healthy volunteers demonstrated dose-dependent increases in muscle mass and decreases in fat mass. Development was voluntarily suspended in 2013 following observations of adverse effects on skin vasculature, including telangiectasias and epistaxis. No subsequent clinical trials have been registered or published.
Clinical Status
ACE-031 (Ramatercept) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "ACE-031"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "ACE-031"
Registered interventional and observational studies, including status and phase.
- PubChem: "ACE-031"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Performance
Melanotan II
Research PhaseA synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocorti...
View detailsIGF-1 LR3 (Long-Arg3)
Research PhaseIGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a s...
View detailsIGF-1 DES (1-3)
Research PhaseIGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (...
View detailsMGF (Mechano Growth Factor)
Research PhaseMechano Growth Factor is a splice variant of the IGF-1 gene expressed in response to mechanical stress on muscle tissue....
View detailsNo lawful pathway today
ACE-031 (Ramatercept) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.